Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy, RK; Loi, S; Okines, A; Paplomata, E; Hamilton, E; Hurvitz, SA; Lin, NU; Borges, V; Abramson, V; Anders, C; Bedard, PL; Oliveira, M; Jakobsen, E; Bachelot, T; Shachar, SS; Müller, V; Braga, S; Duhoux, FP; Greil, R; Cameron, D; Carey, LA; Curigliano, G; Gelmon, K; Hortobagyi, G; Krop, I; Loibl, S; Pegram, M; Slamon, D; Palanca-Wessels, MC; Walker, L; Feng, W; Winer, EP;

View this publication in the PUBMED database